TTANGO, the first randomised trial of a molecular chlamydia and gonorrhoea point-of-care assay

L Natoli, R Guy, B Hengel, L Causer, S Badman, A Tangey, S N Tabrizi, David Whiley, B Donovan, C Fairley, Mark Shephard, D Anderson, H Wand, D Wilson, D Regan, J Ward, J M Kaldor

    Research output: Contribution to conferencePoster

    Abstract

    Background: Point-of-care (POC) tests for sexually transmitted infections may increase timely diagnosis, treatment and partner notification, and thereby reduce community infection rates. With new, portable and highly accurate molecular diagnostic technology available through the GeneXpert®, we designed TTANGO (Test, Treat ANd GO), to measure the effectiveness, cost-effectiveness, cultural and operational acceptability of POC testing for chlamydia (CT) and gonorrhoea (NG) in remote Australian Aboriginal communities, where these infections occur at high levels. The trial employs a crossover, randomised controlled design at 12 health services in remote Australia. We describe the preparatory phase of the trial.
    Original languageEnglish
    Pages251
    Number of pages1
    Publication statusPublished - 23 Oct 2013
    EventAustralasian Sexual Health Conference - Darwin, Australia
    Duration: 21 Oct 201325 Oct 2013

    Conference

    ConferenceAustralasian Sexual Health Conference
    Country/TerritoryAustralia
    CityDarwin
    Period21/10/1325/10/13

    Keywords

    • Chlamydia
    • Gonorrhoea
    • Point-of-Care

    Fingerprint

    Dive into the research topics of 'TTANGO, the first randomised trial of a molecular chlamydia and gonorrhoea point-of-care assay'. Together they form a unique fingerprint.

    Cite this